Business Context and Reporting Period
This Form 8-K was filed by Elevai Labs Inc. (not PMGC Holdings Inc.) on May 3, 2024. The report details the entry into a material definitive agreement with Santorio Biomedical, LLC, effective May 3, 2024. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Newport Beach, CA.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, or margins). The only financial data disclosed relates to the new consulting agreement:
- Consulting Fee: $180,000 per year, payable in monthly installments.
- Equity Compensation: 2,450,000 shares of restricted common stock granted to the Consultant.
- Payment Schedule: Equity to be issued in four installments over ten months.
Material Changes
The primary material change is the execution of a one-year consulting agreement with Santorio Biomedical, LLC for the services of Mr. Deniel Mero. This agreement marks a strategic shift to develop a biotechnology division through the Company's wholly owned subsidiary, Elevai Biosciences Inc.
Outlook, Risks, and Management Commentary
Strategic Objectives: The agreement is designed to support the Company's biotechnology pipeline. Mr. Mero's services include:
- Discovering, assessing, and introducing biotechnology opportunities.
- Advising the Board on strategic matters, including pipeline asset development.
- Recruiting a contract research organization (CRO) and potential directors/team members.
- Forming a scientific advisory board.
Registration Rights: The Company has agreed to register the 2,450,000 granted shares under a registration statement within one year after the final grant installment.
Risks/Contingencies: The filing does not explicitly list new risks, though the agreement is contingent on the performance of services by an independent contractor.
Investor Verification Checklist
- Verify the exact vesting schedule and conditions for the 2,450,000 restricted shares.
- Review the full text of the Consulting Agreement (Exhibit 10.1) for termination clauses and specific deliverables.
- Confirm the dilution impact of the 2,450,000 shares on existing shareholders.
- Monitor future filings for the registration statement required for the granted shares.